Physician profile
Anna Suponya
NPI 1043210669
$1,441.42
in general payments reported to CMS, 2019-2025
13 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.72 · 2020: $245 · 2021: $331 · 2022: $226 · 2023: $168 · 2024: $277 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.58 | 2020-2025 | Ubrelvy |
| Lilly USA, LLC | $327.29 | 2020-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $137.24 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $98.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $71.05 | 2024 | Farxiga |
| Amgen INC. | $29.97 | 2023 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $28.31 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $23.33 | 2021 | |
| Intra-Sana Laboratories | $21.78 | 2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Amarin Pharma, INC. | $20.84 | 2020 | |
| Novo Nordisk INC | $17.99 | 2024 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Suponya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.